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Abstract 23
African swine fever virus (ASFV) is the etiological agent of a contagious and often lethal disease 24 of domestic pigs that has significant economic consequences for the swine industry. The disease is 25 devastating the swine industry in Central Europe and East Asia, with current outbreaks caused by 26 circulating strains of ASFV derived from the 2007 Georgia isolate (ASFV-G), a genotype II ASFV. In 27 the absence of any available vaccines, African Swine Fever (ASF) outbreak containment relies on 28 control and culling of infected animals. Limited cross protection studies suggest that in order to ensure a 29 vaccine is effective it must be derived from the current outbreak strain or at the very least from an 30 isolate with the same genotype. Here we report the discovery that deletion of a previously 31 uncharacterized gene, I177L, from the highly virulent ASFV-G produces complete virus attenuation in 32 swine. Animals inoculated intramuscularly with the virus lacking the I177L gene, ASFV-G-ΔI177L, in a 33 dose range of 10 2 to 10 6 HAD 50 remained clinically normal during the 28 day observational period. All 34 ASFV-G-ΔI177L-infected animals had low viremia titers, showed no virus shedding, developed a strong 35 virus-specific antibody response and, importantly, they were protected when challenged with the 36 virulent parental strain ASFV-G. ASFV-G-ΔI177L is one of the few experimental vaccine candidate 37 virus strains reported to be able to induce protection against the ASFV Georgia isolate, and the first 38 vaccine capable of inducing sterile immunity against the current ASFV strain responsible for recent 39 outbreaks. 40 41
Importance: 42
Currently there is no commercially available vaccine against African swine fever. Outbreaks of 43 this disease are devastating the swine industry from Central Europe to East Asia, and they are being 44 caused by circulating strains of African swine fever virus derived from the Georgia2007 isolate. Here we 45 report the discovery of a previously uncharacterized virus gene, which when deleted completely 46 attenuates the Georgia isolate. Importantly, animals infected with this genetically modified virus were 47 protected from developing ASF after challenge with the virulent parental virus. Interestingly, ASFV-G-48 ΔI177L confers protection even at low doses (10 2 HAD 50 ) and remains completely attenuated when 49 inoculated at high doses (10 6 HAD 50 ), demonstrating its potential as a safe vaccine candidate. At 50 medium doses (10 4 HAD 50 ) sterile immunity is achieved. Therefore, ASFV-G-ΔI177L is a novel 51 efficacious experimental ASF vaccine protecting pigs from the epidemiologically relevant ASFV 52 Georgia isolate. 53 54 Introduction 55
African Swine Fever (ASF) is a contagious and often fatal viral disease of swine. The causative 56 agent, ASF virus (ASFV), is a large enveloped virus containing a double-stranded (ds) DNA genome of 57 approximately 190 kilobase pairs (1). ASFV shares aspects of genome structure and replication strategy 58 with other large dsDNA viruses, including the Poxviridae, Iridoviridae and Phycodnaviridae (2). 59 However, on a protein or amino acid level there is little homology with the majority of the viral proteins, 60 and very few ASFV proteins have been evaluated for their functionality or for their contribution to virus 61
pathogenesis. 62
Currently, ASF is endemic in more than twenty sub-Saharan African countries. In Europe, ASF 63 is endemic on the island of Sardinia (Italy) and outbreaks in additional countries began with an outbreak 64 in the Caucasus region in 2007, affecting Georgia, Armenia, Azerbaijan and Russia. ASF has continued 65 to spread uncontrollably across Europe and Asia with ASFV outbreaks occurring in 2018 Mongolia, Vietnam, Laos, Cambodia, Serbia, Myanmar, North Korea and the Philippines. ASF has also 67 spread to wild boar in Belgium, but has been restricted to a quarantine zone since the first introduction 68 of the disease in 2018. Sequencing of several contemporary epidemic ASFVs suggests high nucleotide 69 similarity with only minor modifications compared to the initial 2007 outbreak strain, ASFV Georgia 70 2007/1, a highly virulent isolate that belongs to the ASFV genotype II group (3) . 71
There is no vaccine available for ASF and disease outbreaks are currently quelled by animal 72 quarantine and slaughter. Attempts to vaccinate animals using infected cell extracts, supernatants of 73 infected pig peripheral blood leukocytes, purified and inactivated virions, infected glutaraldehyde-fixed 74 macrophages, or detergent-treated infected alveolar macrophages failed to induce protective immunity 75 (4-7). Protective immunity develops in pigs surviving viral infection with moderately virulent or 76 attenuated variants of ASFV, with long-term resistance to homologous, but rarely to heterologous, virus 77 challenge (8, 9) . Significantly, pigs immunized with live attenuated ASF viruses containing genetically 78 engineered deletions of specific ASFV virulence-associated genes are protected when challenged with 79 homologous parental virus (10-15). These observations constitute the only experimental evidence 80 describing the rational development of an effective live attenuated vaccine against ASFV. 81
Here we report the discovery that deletion of a previously uncharacterized gene, I177L, from the 82 highly virulent ASFV Georgia isolate (ASFV-G) results in complete attenuation in swine. Animals 83 inoculated with the virus lacking the I177L gene, ASFV-G-ΔI177L, remained clinically normal, 84 developed a strong virus-specific antibody response and, importantly, ASFV-G-ΔI177L-infected swine 85 were completely protected when challenged with the virulent parental ASFV-G. 86 87 88
Materials and Methods 89

Cell culture and viruses 90
Primary swine macrophage cell cultures were prepared from defibrinated swine blood as 91 previously described (15). Briefly, heparin-treated swine blood was incubated at 37°C for 1 hour to 92 allow sedimentation of the erythrocyte fraction. Mononuclear leukocytes were separated by flotation 93 over a Ficoll-Paque (Pharmacia, Piscataway, N.J.) density gradient (specific gravity, 1.079 were detached from the plastic by using 10 mM EDTA in phosphate buffered saline (PBS) and were 99 then reseeded into Primaria T25, 6-or 96-well dishes at a density of 5x10 6 cells per ml for use in assays 100 24 hours later. 101
Comparative growth curves between ASFV-G and ASFV-G-ΔI177L viruses were performed in 102 primary swine macrophage cell cultures. Preformed monolayers were prepared in 24-well plates and 103 infected at a MOI of 0.01 (based on HAD 50 previously determined in primary swine macrophage cell 104 cultures). After 1 hour of adsorption at 37°C under 5% CO 2 the inoculum was removed and the cells 105 were rinsed two times with PBS. The monolayers were then rinsed with macrophage media and 106 incubated for 2, 24, 48, 72 and 96 hours at 37°C under 5% CO 2 . At appropriate times post-infection, the 107 cells were frozen at <−70°C and the thawed lysates were used to determine titers by HAD 50 /ml in 108 primary swine macrophage cell cultures. All samples were run simultaneously to avoid inter-assay 109 variability. 110
Virus titration was performed on primary swine macrophage cell cultures in 96-well plates. Virus 111 dilutions and cultures were performed using macrophage medium. Presence of virus was assessed by 112 hemadsorption (HA) and virus titers were calculated by the Reed and Muench method (16) . 113 ASFV Georgia (ASFV-G) was a field isolate kindly provided by Dr. Nino Vepkhvadze, from the 114 Laboratory of the Ministry of Agriculture (LMA) in Tbilisi, Republic of Georgia. 115
Microarray analysis 116
The microarray data of ASFV open reading frames were obtained from the data set deposited in 117 NCBI databases by Zhu et al. (submitted) . In brief, total RNA was extracted from primary swine 118 macrophage cell cultures infected with ASFV Georgia strain or mock infected at 3, 6, 9, 12, 15, and 18 119 hours post-infection (hpi). A custom designed porcine microarray manufactured by Agilent 120
Technologies (Chicopee, MA) was used for this study. Both infected and mock-infected RNA samples 121 were labeled with Cy3 and Cy5 using an Agilent low-input RNA labeling kit (Agilent Technologies). 122 Cy5-labeled infected or mock-infected samples were co-hybridized with Cy3-labeled mock-infected or 123 infected samples in one array, respectively, for each time point using a dye-swap design. The entire 124 procedure of microarray analysis was conducted according to protocols, reagents and equipment 125 provided or recommended by Agilent Technologies. Array slides were scanned using a GenePix 4000B 126 scanner (Molecular Devises, San Jose, CA) with the GenePix Pro 6.0 software at 5 μm resolution. 127
Background signal correction and data normalization of the microarray signals and statistical analysis 128 were performed using the LIMMA package. The signal intensities of ASFV open reading frame RNA 129 were averaged from both Cy3 and Cy5 channels. 130
Construction of the recombinant ASFV-G-ΔI177L 131
Recombinant ASFVs were generated by homologous recombination between the parental ASFV-132 G genome and recombination transfer vector by infection and transfection procedures using swine 133 macrophage cell cultures (15). Recombinant transfer vector (p72mCherryΔI177L) containing flanking 134 genomic regions to amino acids 112 though 150 of the I177L gene, mapping approximately 1kbp to the 135 left and right of these amino acids, and a reporter gene cassette containing the mCherry gene with the 136 ASFV p72 late gene promoter, p72mCherry, was used. This construction created a 112 bp deletion in 137 the I177L ORF ( Fig. 1 ). Recombinant transfer vector p72mCheryΔI177L was obtained by DNA 138 synthesis (Epoch Life Sciences Missouri City, TX, USA). 139
Next Generation Sequencing (NGS) of ASFV genomes 140
ASFV DNA was extracted from infected cells and quantified as described earlier. Full-length 141 sequence of the virus genome was performed as described previously (17) ASFV-G-ΔI177Lwas assessed for its virulence phenotype relative to the virulent parental ASFV-149 G virus using 80-90 pound commercial breed swine. Groups of pigs (n=5) were inoculated 150 intramuscularly (IM) either with 10 2 -10 6 HAD 50 of ASFV-G ΔI177L or 10 2 HAD 50 of parental ASFV-151 G virus. Clinical signs (anorexia, depression, fever, purple skin discoloration, staggering gait, diarrhea 152 and cough) and changes in body temperature were recorded daily throughout the experiment. In 153 protection experiments, animals inoculated with ASFV-GΔI177L were 28 days later IM challenged with 154 10 2 HAD 50 of parental virulent ASFV-G strain. Presence of clinical signs associated with the disease 155 was recorded as described earlier. 156
Detection of anti-ASFV antibodies 157
ASFV antibody detection used an in-house indirect ELISA, developed as described previously 158 (18). Briefly, ELISA antigen was prepared from ASFV-infected Vero cells. Maxisorb ELISA plates 159 (Nunc, St Louis, MO, USA) were coated with 1 µg per well of infected or uninfected cell extract. The 160 plates were blocked with phosphate-buffered saline containing 10% skim milk (Merck, Kenilworth, NJ, 161 USA) and 5% normal goat serum (Sigma, Saint Louis, MO). Each swine serum was tested at multiple 162 dilutions against both infected and uninfected cell antigen. ASFV-specific antibodies in the swine sera 163 were detected by an anti-swine IgM or IgG-horseradish peroxidase conjugate (KPL, Gaithersburg, MD, 164 USA) and SureBlue Reserve peroxidase substrate (KPL). Plates were read at OD630 nm in an ELx808 165 plate reader (BioTek, Shoreline, WA, USA). Sera titers were expressed as the log10 of the highest 166 dilution where the OD630 reading of the tested sera at least duplicates the reading of the mock infected 167 sera. 168
169
Results 170
Conservation of I177L gene across different ASFV isolates 171
ASFV-G ORF I177L encodes for a 177 amino acid protein and is positioned on the reverse 172 strand between nucleotide positions 174471 and 175004 of the ASFV-G genome (Fig. 1) . The degree of 173 I177L conservation among ASFV isolates was examined by multiple alignment using CLC genomics 174 workbench software (CLCBio; Aarhus, Denmark). The ASFV I177L protein sequences were derived 175 from all sequenced isolates of ASFV representing African, European and Caribbean isolates from 176 domestic pig, wild pig, and tick sources. I177L has a predicted protein length of 161 to 177 amino acid 177 residues depending on the isolate. Most of the isolates contain a protein with a length of 177 amino 178 acids, with a few isolates showing a truncated C-terminus that yield a protein of 161-162 amino acids. It 179 is predicted that I177L contains a possible N-terminal transmembrane helix (data not shown). I177L is 180 sometimes annotated in recent isolates using a different start codon that occurs at position 112, 181 however this has been recently shown to be a sequencing mistake in the annotation of these 182 genomes (19) . I177L at the amino acid level revealed a very high degree of amino acid identity among 183
isolates when compared to isolates containing the same or different forms of I177L ( Fig. 1) . 184
I177L gene is transcribed as a late gene during the virus replication cycle 185
The time of transcription of the I177L gene was determined by microarray evaluating total RNA 186 extracted from primary swine macrophage cell cultures infected with ASFV-G at 3, 6, 9, 12, 15, and 18 187 hours hpi (representing an approximate one life cycle of ASFV replication). 188 Figure 2 shows the microarray signal intensities of three ASFV open reading frames at the six 189 time points sampled. CP204L gene (encoding for ASFV protein p30) was expressed at approximate 41k 190 photons per pixel at 3 hpi, which agrees with its known early gene expression after ASFV infection. The 191 expression gradually decreased at 6 and 9 hpi and then significantly increased by more than 9-fold, 192 reaching a plateau at 12 hpi. In contrast, B646L, a p72 virus capsid protein gene known for its late 193 expression, was practically not expressed at 3 hpi at a level less than 20 photons per pixel. The p72 194 expression significantly increased to >44k at 6 hpi and reached a plateau at 12 hpi. I177L appears to be a 195 late expressed gene much like B646L. The I177L gene was transcribed at less than 50 photons per pixel 196 at 3 hpi. Unlike the p72 gene, I177L expression increased linearly at a much slower rate and its 197 expression remained low at 18 hpi. 198
Development of the I177L gene deletion mutant of the ASFV-Georgia isolate 199
To 
Replication of ASFV-G-ΔI177L in primary swine macrophages 217
In vitro growth characteristics of ASFV-G-ΔI177L were evaluated in primary swine macrophage 218 cell cultures, the primary cell targeted by ASFV during infection in swine and compared relative to 219 parental ASFV-G in multistep growth curves (Fig. 4) . Cell cultures were infected at a MOI of 0.01 and 220 samples were collected at 2, 24, 48, 72 and 96 hours post-infection (hpi). Results demonstrated that 221 ASFV-G-ΔI177L displayed a growth kinetic significantly decreased when compared to parental ASFV-222 G. ASFV-G-ΔI177L yields are approximately 100 to 1,000-fold lower than those of ASFV-G depending 223 on the time point considered. Therefore, deletion of the I177L gene significantly decreased the ability of 224 ASFV-G-ΔI177L, relative to the parental ASFV-G isolate, to replicate in vitro in primary swine 225 macrophage cell cultures. 226
Assessment of ASFV-G-ΔI177L virulence in swine 227
To evaluate the degree of attenuation reached by ASFV-G-ΔI177L, a preliminary experiment 228 was performed using low virus load. A group of 80-90 pounds pigs were inoculated via IM with 10 2 229 HAD 50 ASFV-G-ΔI177L and compared with animals inoculated with 10 2 HAD of parental ASFV-G. All 230 five animals inoculated with ASFV-G had increased body temperature (>104 °F ) by day 5 post-231 infection, presenting with clinical signs associated with the disease including anorexia, depression, 232 purple skin discoloration, staggering gait and diarrhea (Table 1) . Signs of the disease aggravated 233 progressively over time and animals were euthanized in extremis by 7 days post-infection (pi). 234
Conversely, the five animals inoculated via IM with ASFV-G-ΔI177L did not present with any ASF-235 related signs, remaining clinically normal during the entire 28-day observation period. 236
Animals infected with ASFV-G presented with expected high homogenous titers (10 7.5 -10 8.5 237 HAD 50 /ml) on day 4 pi, increasing (around 10 8.5 HAD 50 /ml) by day 7 pi when all animals were 238 euthanized. Conversely, ASFV-G-ΔI177L revealed a different pattern with low viremia (10 1.8 -10 5 239 HAD 50 /ml) at day 4 pi, reaching peak values (10 4 -10 7.5 HAD 50 /ml) by day 11 pi and then decreasing 240 titers (10 2.3 -10 4 HAD 50 /ml) until day 28 pi (Fig. 5 ). It should be noted that one of the five animals 241 inoculated with ASFV-G-ΔI177L showed a remarkably lower viremia (1,000-to 10,000-fold lower 242 depending on the time point considered) than the average viremia values of the other animals in the 243 group. Therefore, deletion of the I177L gene produced complete attenuation of the parental highly 244 virulent ASFV-G virus when inoculated at a low dose, with the infected animals presenting long 245 viremias with relatively low values. 246
To investigate the potential presence of residual virulence in ASFV-G-ΔI177L a second 247 experiment was performed where different groups of five pig were infected IM with either 10 2 , 10 4 , or 248 10 6 HAD 50 of ASFV-G-ΔI177L and their behavior compared with that of naïve animals inoculated with 249 10 2 HAD 50 of parental ASFV-G. In addition, a mock infected animal cohabitated in each of the groups, 250 acting as a sentinel to detect potential virus shedding from the infected animals. 251
As in the first experiment, animals inoculated with ASFV-G exhibited all typical clinical signs 252 of the disease and were euthanized in extremis by day 6-7 pi ( Table 2) . Interestingly all animals 253 inoculated with ASFV-G-ΔI177L, including those receiving 10 6 HAD 50 , did not present any ASF-254 related signs, remaining clinically normal during the entire observation period (28 days). Similarly, all 255 sentinel animals remained clinically normal (Fig. 6) . 256
Viremia kinetics in ASFV-G-infected animals presented high titers (10 3.5 -10 8 HAD 50 /ml) on day 257 4 pi increasing (around 10 7.5 HAD 50 /ml) by day 6-7 pi when all animals were euthanized (Fig. 7) . 258
Animals infected with 10 2 HAD 50 /ml of ASFV-G-ΔI177L showed similar results to those seen in the 259 previous experiment although this time viremias were not detected until day 11 pi (with the exception of 260 one animal) and two out of the five animals presented significantly lower titers than the other three 261 animals in the group. In the groups of animals infected with 10 4 or 10 6 HAD 50 /ml of ASFV-G-ΔI177L, 262 viremias were clearly detectable at 4 days pi with average values remarkably higher (1,000-to 10,000-263 fold) than the group inoculated with 10 2 HAD 50 /ml particularly, at 4 and 7 days pi. Heterogeneity in the 264 viremia measurements is also seen in the groups inoculated with the higher doses of ASFV-G-ΔI177L 265 particularly at 21 and 28 days pi when 3 animals in each group presented remarkably lower titers than 266 the other two animals in the group. Therefore, deletion of the I177L gene produced a complete 267 attenuation of the parental highly virulent ASFV-G virus even when used at high dosage, with the 268 infected animals presenting low-titer viremias that persisted throughout the duration of the 28-day 269 observational period. Interestingly, no virus was detected in any of the samples (all sampled blood time 270 points as well as tonsil and spleen samples obtained at 28 days pi) obtained from sentinel animals (data 271 not shown), indicating that ASFV-G-ΔI177L-infected animals did not shed enough virus to infect naïve 272 pigs during the 28 days of cohabitation. 273
Protective efficacy of ASFV-G-ΔI177L against challenge with parental ASFV-G 274
To assess the ability of ASFV-G-ΔI177L infection to induce protection against challenge with 275 highly virulent parental virus ASFV-G, all animals infected with ASFV-G-ΔI177L were challenged 28 276 days later with 10 2 HAD 50 of ASFV-G by IM route. Five naïve animals were challenged as a mock-277 inoculated control group. 278
All mock animals started showing disease-related signs by 3-4 days post challenge (dpc), with 279 rapidly increasing disease severity in the following hours and being euthanized by 5-6 dpc ( Table 3 ). On 280 the other hand, the three groups of animals infected with ASFV-G-ΔI177L remained clinically healthy, 281 not showing any significant signs of disease during the 21-day observational period. Therefore, ASFV-282 G-ΔI177L-treated animals are protected against clinical disease when challenged with the highly 283 virulent parental virus. 284
Analysis of viremia in animals infected with ASFV-G presented with expected high titers (10 7.3 -285 10 8.3 HAD 50 /ml) on day 4 pi, increasing (averaging 10 8.5 HAD 50 /ml) by the time when all animals were 286 euthanized. After challenge, none of the ASFV-G-ΔI177L-infected animals had viremias with values 287 higher than those present at challenge and viremia values decreased progressively until the end of the 288 experimental period (21 days after challenge) when, importantly, no circulating virus could be detected 289 in blood from any of these animals (Fig. 7) . Interestingly, post-challenge viremia titers, calculated by 290 HA, exactly coincide with those calculated by fluorescence suggesting a lack (or at least a very low rate) 291 of replication by the challenge virus. To assess the potential replication of the challenge virus the 292 presence of ASFV-G was tested in blood samples taken at day 4 post challenge, when the highest 293 viremia titers occur after challenge (Fig. 7) . Using an I177L-specific real-time PCR to detect only 294 challenge virus (with a demonstrated sensitivity of approximately 10 HAD 50 ) all blood samples tested 295 negative but one from an animal infected with 10 2 HAD 50 of ASFV-G-ΔI177L (data not shown). 296 Furthermore, tonsils and spleen samples were obtained from all ASFV-G-ΔI177L infected animals at the 297 end of the observational period (21 days post-challenge) and tested for the presence of virus (detected by 298 hemoadsoption) using swine macrophage cultures. Most of the animals in each group had infectious 299 virus either in tonsils or spleen (data not shown). All positive samples were then assessed using the 300 I177L-specific real-time PCR, detecting the presence of the challenge virus in only one spleen belonging 301 to the same animal initially infected with 10 2 HAD 50 /ml of ASFV-G-ΔI177L, which also had challenge 302 virus in the blood (data not shown). These results suggest that replication of challenge virus was absent 303 in all infected animals receiving 10 4 HAD 50 /ml or higher and most of the animals receiving 10 2 304 HAD 50 /ml of ASFV-G-ΔI177L. 305
Host antibody response in animals infected with ASFV-G-ΔI177L 306
Host immune mechanisms mediating protection against virulent strains of ASFV in animals 307 infected with attenuated strains of virus are not well identified (20) (21) (22) . Our previous experience 308 indicated that the only parameter consistently associated with protection against challenge is the level of 309 circulating antibodies (18). In order to gain additional understanding of immune mechanisms in ASFV-310 G-ΔI177L-infected animals, we attempted to correlate the presence of anti-ASFV circulating antibodies 311 with protection. ASFV-specific antibody response was detected in the sera of these animals using two 312 in-house developed direct ELISAs (18). All animals infected with ASFV-G-ΔI177L, regardless of the 313 dose of virus received, possessed similar high titers of circulating anti-ASFV antibodies (Fig. 8) . 314 Antibody response, mediated by IgM and IgG isotypes, was detected in all three groups by day 12 pi. By 315 day 14 pi response mediated by both antibody isotypes reached maximum levels in all groups. IgM-316 mediated antibody response disappeared in all animals by day 21 pi, while IgG mediated response 317 remained high with minimal fluctuation until day 28 pi without significant differences between animals 318 in the three groups inoculated with ASFV-G-ΔI177L. Therefore, as described in our previous reports 319 (14, 18) there is a close correlation between presence of anti-ASFV antibodies at the moment of 320 challenge and protection. It should be mentioned that no antibodies were detected in any serum sample 321 obtained from the sentinel animals corroborating the virological data indicating that sentinel animals 322 were not infected from ASFV-G-ΔI177L infected animals in any of the three groups (data not show). 323
Discussion 324
The use of attenuated strains is currently the most plausible approach to develop an effective 325 ASF vaccine. Rational development of attenuated strains by genetic manipulation is a valid alternative, 326 and perhaps safer methodology, compared to the use of naturally attenuated isolates. Several attenuated 327 strains, obtained by genetic manipulation consisting of deletions of single genes or a group of genes, 328 have been shown to induce protection against the virulent parental virus (10-13, 15, 23) . Here, the 329 identification of a previously uncharacterized ASFV gene, I177L, as a viral genetic determinant of 330 virulence is described. Deletion of I177L completely attenuates ASFV-G in swine, even when used at 331 doses as high as 10 6 HAD 50 . Only two other genetic modifications have been shown to completely 332 abolish virulence in the highly virulent ASFV Georgia isolate: deletion of the 9GL gene (particularly 333 potentiated by the additional deletion of the UK gene) and deletion of a group of six genes from the 334 MGF360 and 530 (12, 13, 24) . The attenuation observed by deleting the I177L gene is a remarkable 335 discovery since ASFV-G has not been efficiently attenuated by deletion of any other genes that have 336 been associated with attenuation in other ASFV isolates (13, 25) . Based on the cumulative efforts 337 supported by several studies, it is apparent that the genetic background where deletion is operated plays 338 a critical role in the effect of a particular gene in virus virulence supporting the concept that AFV 339 virulence is the result of the interactive effect of several virus genes. 340
Although ASFV-G-ΔI177L-infected animals remained clinically normal, all of them presented 341 with viremia by 28 days pi, in some cases with relatively high titers. Interestingly, no infectious virus or 342 virus specific antibodies could be detected in any of the three sentinels indicating that transmission of 343 ASFV-G-ΔI177L from infected to naïve animals is not a frequent event, a desirable characteristic for a 344 potential candidate live attenuated vaccine. 345 Importantly, animals infected with ASFV-G-ΔI177L were effectively protected when challenged 346 at 28 dpi. Protection was achieved with doses as low as 10 2 HAD 50 of ASFV-G-ΔI177L while even the 347 administration of 10 6 HAD 50 ASFV-G-ΔI177L did not produce any disease-associated signs (not even a 348 transient rise in body temperature), emphasizing the safety of ASFV-G-ΔI177L as a potential vaccine 349 candidate. Importantly, it appears that replication of the challenge virus in the ASFV-G-ΔI177L-infected 350 animals is quite restricted since challenge virus was isolated from only one of the animals inoculated 351 with the low dose of Although the host mechanisms mediating protection against ASFV infection remain under 353 discussion (1, 2), in our experience with different live attenuated vaccine candidates we have been 354 observing a close association between presence of circulating virus-specific antibodies and protection 355 (12-14, 24, 26) . In this report, we were also able to associate presence of virus specific antibodies and 356 protection. Interestingly, regardless of the ASFV-G-ΔI177L dose used, all animals had similar antibody 357 titers at the time of challenge, supporting the fact that low doses of ASFV-G-ΔI177L were as effective 358 as the highest dose. A note is the fact that by day 14 pi, all animals reached maximum antibody titers. 359
Although in this report challenge was not performed at 14 dpi this data agrees with previous published 360 reports demonstrating that animals inoculated with vaccine candidate ASFV-G-Δ9GL/ΔUK presenting 361 with circulating antibodies were protected against challenge at 2 weeks post-infection 24 . 362
We believe results presented here demonstrate that ASFV-G-ΔI177L can be considered a strong 363 vaccine candidate to protect animals against the ASFV Georgia isolate and its derivatives currently 364 causing outbreaks in a wide geographical area from central Europe to China and Southeast Asia. The 365 complete lack of residual virulence, even when administered at high doses, apparent low levels of 366 transmissibility to naïve animals, and its high efficacy in inducing protection even at low doses makes 367 ASFV-G-ΔI177L a promising novel vaccine candidate. 368
369
Acknowledgements 370 ASFV-G-ΔI177L 10 6 HAD 50 5/5 ---103 (0.43)
479
(1) All animals were euthanized due to humanitarian reasons following the corresponding IACUC 480 protocol. 481 ASFV-Georgia-ΔI177L (filled symbols), mock inoculated (sentinels, showed in red) or 10 2 HAD 50 of 502 ASFV-G (empty symbols) (panels on the left), and after the challenge with 10 2 HAD 50 of ASFV-G 503 (panels on the right). Each curve represents individual animals values in each of the group. 504 Fig. 7 : Viremia titers detected in pigs IM inoculated with either (A) 10 2 , 10 4 , or 10 6 HAD 50 of ASFV-505 Georgia-ΔI177L or 10 2 HAD 50 of ASFV-G. (B) Viremia after the challenge with 10 2 HAD 50 of ASFV-G 506
Each curve represents values from individual animals in each of the group. Sensitivity of virus detection: 507 > 1.8 log 10 HAD 50 /ml 50 /ml. Data from sentinel animals are depicted in red. 508 
